Addendum—Some stemcell-transplant surgeons claim to be “unimpressed” with such CAR-T therapies as Yescarta and Breyanzi. The reason for such a viewpoint, sadly, may be that these specialists are worried about losing business.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”